Cargando…
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
OBJECTIVE: Evaluating the efficacy of 3,6’‐dithioPomalidomide in 5xFAD Alzheimer's disease (AD) mice to test the hypothesis that neuroinflammation is directly involved in the development of synaptic/neuronal loss and cognitive decline. BACKGROUND: Amyloid‐β (Aβ) or tau‐focused clinical trials h...
Autores principales: | Lecca, Daniela, Jung, Yoo Jin, Scerba, Michael T., Hwang, Inho, Kim, Yu Kyung, Kim, Sun, Modrow, Sydney, Tweedie, David, Hsueh, Shih‐Chang, Liu, Dong, Luo, Weiming, Glotfelty, Elliot, Li, Yazhou, Wang, Jia‐Yi, Luo, Yu, Hoffer, Barry J., Kim, Dong Seok, McDevitt, Ross A., Greig, Nigel H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437140/ https://www.ncbi.nlm.nih.gov/pubmed/35234334 http://dx.doi.org/10.1002/alz.12610 |
Ejemplares similares
-
Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury
por: Hsueh, Shih Chang, et al.
Publicado: (2022) -
Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments
por: Jung, Yoo Jin, et al.
Publicado: (2019) -
Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury
por: Lecca, Daniela, et al.
Publicado: (2023) -
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018) -
Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018)